1621908-76-6

Basic information

• Product Name: N-((S)-1-(((R)-3-methyl-1-((3aR,4R,6R,7aS)-5,5,7a-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)amino)-1-oxo-3-phenylpropan-2-yl)benzamide
• Synonyms: N-((S)-1-(((R)-3-methyl-1-((3aR,4R,6R,7aS)-5,5,7a-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)amino)-1-oxo-3-phenylpropan-2-yl)benzamide
• CAS NO: 1621908-76-6
• Molecular Weight: 516.489
• Mol File: 1621908-76-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-((S)-1-(((R)-3-methyl-1-((3aR,4R,6R,7aS)-5,5,7a-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)amino)-1-oxo-3-phenylpropan-2-yl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-((S)-1-(((R)-3-methyl-1-((3aR,4R,6R,7aS)-5,5,7a-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)amino)-1-oxo-3-phenylpropan-2-yl)benzamide(1621908-76-6)
• EPA Substance Registry System: N-((S)-1-(((R)-3-methyl-1-((3aR,4R,6R,7aS)-5,5,7a-trimethylhexahydro-4,6-methanobenzo[d][1,3,2]dioxaborol-2-yl)butyl)amino)-1-oxo-3-phenylpropan-2-yl)benzamide(1621908-76-6)

Safety Data

• Hazardous Substances Data: 1621908-76-6(Hazardous Substances Data)

Upstream product

• 7364-51-4 N,O-bis(trimethylsilyl)phenylalanine 
• 63-91-2 L-phenylalanine 
• 2566-22-5 N-benzoyl-L-phenylalanine 
• 10364-94-0 1-benzoylimidazole 
• 65-85-0 benzoic acid 

Downstream Products

• 179324-79-9 ((R)-1-((S)-2-benzamido-3-phenylpropanamido)-3-methylbutyl)boronic Acid 

Relevant articles and documents

Bortezomib congeners induce apoptosis of hepatocellular carcinoma via CIP2A inhibition

CIP2A is an oncoprotein that upregulates p-Akt and promotes cancer cell proliferation and survival. The proteasome inhibitor bortezomib has been shown to reduce CIP2A and lead to cell apoptosis. Here; we modified the functional group of bortezomib to generate a series of novel compounds and conducted a structure-activity relationship (SAR) study. The results showed that compound 1 was able to repress CIP2A expression and cell apoptosis in the same manner as bortezomib, but with less potency in inhibition of proteasome activity. This finding provides a new direction for the design of CIP2A inhibitors.